Rothschild & Co Upgrades Abbott Laboratories to Buy, Raises Price Target to $127

Rothschild & Co analyst Ed Ridley-Day upgrades Abbott Laboratories (NYSE:ABT) from Neutral to Buy and raises the price target from $119 to $127.